Clal Insurance Enterprises Holdings Ltd Sells 300,000 Shares of Cellebrite DI Ltd. $CLBT

Key Points

• Clal Insurance Enterprises Holdings trimmed its Cellebrite DI stake by 8.6% in the first quarter, selling 300,000 shares and leaving it with 3.17 million shares worth about $43.7 million.
• Insider selling continued, with CEO Thomas E. Hogan selling 103,188 shares and CRO Marcus Jewell selling 12,658 shares; insiders have sold 158,191 shares over the last 90 days.
• Analyst sentiment remains cautiously positive: the stock has a “Moderate Buy” consensus rating, with an average price target of $21.40, even as some firms adjusted their targets.

Clal Insurance Enterprises Holdings Ltd cut its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 8.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,173,014 shares of the company's stock after selling 300,000 shares during the quarter. Clal Insurance Enterprises Holdings Ltd owned about 1.27% of Cellebrite DI worth $43,724,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Cellebrite DI by 16.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company's stock valued at $3,362,000 after acquiring an additional 24,881 shares during the period. Geode Capital Management LLC raised its position in shares of Cellebrite DI by 16.2% in the second quarter. Geode Capital Management LLC now owns 314,440 shares of the company's stock valued at $5,029,000 after purchasing an additional 43,898 shares during the period. Invesco Ltd. lifted its stake in shares of Cellebrite DI by 6.4% during the 2nd quarter. Invesco Ltd. now owns 3,505,552 shares of the company's stock valued at $56,089,000 after buying an additional 209,473 shares in the last quarter. First Trust Advisors LP purchased a new stake in shares of Cellebrite DI during the 2nd quarter valued at approximately $341,000. Finally, Marshall Wace LLP bought a new position in Cellebrite DI in the 2nd quarter worth approximately $4,472,000. Institutional investors own 45.88% of the company's stock.

Insider Activity

In other news, CEO Thomas E. Hogan sold 103,188 shares of the business's stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $15.76, for a total transaction of $1,626,242.88. Following the completion of the transaction, the chief executive officer owned 590,777 shares of the company's stock, valued at approximately $9,310,645.52. The trade was a 14.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CRO Marcus Jewell sold 12,658 shares of the company's stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $12.77, for a total transaction of $161,642.66. Following the completion of the transaction, the executive owned 440,101 shares in the company, valued at approximately $5,620,089.77. This trade represents a 2.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 158,191 shares of company stock worth $2,479,438. 5.70% of the stock is currently owned by insiders.

Cellebrite DI Stock Down 4.0%

Cellebrite DI stock opened at $14.75 on Wednesday. Cellebrite DI Ltd. has a 52 week low of $11.02 and a 52 week high of $19.98. The business has a 50-day simple moving average of $14.10 and a 200 day simple moving average of $14.36. The stock has a market cap of $3.68 billion, a price-to-earnings ratio of 52.68, a PEG ratio of 1.90 and a beta of 1.17.

Analyst Ratings Changes

A number of equities analysts have recently commented on CLBT shares. Weiss Ratings raised Cellebrite DI from a "sell (d+)" rating to a "hold (c-)" rating in a report on Monday, May 18th. DA Davidson initiated coverage on Cellebrite DI in a research report on Wednesday, May 27th. They set a "buy" rating and a $20.00 price target on the stock. Finally, Needham & Company LLC lowered their price target on shares of Cellebrite DI from $18.00 to $15.00 and set a "buy" rating on the stock in a report on Friday, May 15th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Cellebrite DI currently has a consensus rating of "Moderate Buy" and an average target price of $21.40.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.

Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.